메뉴 건너뛰기




Volumn 8, Issue 2, 2013, Pages 126-142

The use of Cytokines and chemokines in the cancer immunotherapy

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; CXCL13 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

EID: 84875305586     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574892811308020002     Document Type: Review
Times cited : (52)

References (174)
  • 1
    • 0035901090 scopus 로고    scopus 로고
    • Inflammation and cancer: Back to Virchow?
    • Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357(9255): 539-45.
    • (2001) Lancet , vol.357 , Issue.9255 , pp. 539-545
    • Balkwill, F.1    Mantovani, A.2
  • 2
    • 0022891340 scopus 로고
    • Tumors: Wounds that do not heal: Similarities between tumor stroma generation and wound healing
    • Dvorak HF. Tumors: Wounds that do not heal: Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315(26): 1650-9.
    • (1986) N Engl J Med , vol.315 , Issue.26 , pp. 1650-1659
    • Dvorak, H.F.1
  • 4
    • 84857141296 scopus 로고    scopus 로고
    • Cancer-related inflammation: Common themes and therapeutic opportunities
    • Balkwill FR, Mantovani A. Cancer-related inflammation: Common themes and therapeutic opportunities. Semin Cancer Biol 2012; 22(1): 33-40.
    • (2012) Semin Cancer Biol , vol.22 , Issue.1 , pp. 33-40
    • Balkwill, F.R.1    Mantovani, A.2
  • 5
    • 79956191029 scopus 로고    scopus 로고
    • Chronic inflammation and cancer: The role of the mitochondria
    • Kamp DW, Shacter E, Weitzman SA. Chronic inflammation and cancer: The role of the mitochondria. Oncology (Williston Park) 2011; 25(5): 400-10.
    • (2011) Oncology (Williston Park) , vol.25 , Issue.5 , pp. 400-410
    • Kamp, D.W.1    Shacter, E.2    Weitzman, S.A.3
  • 6
    • 84875354135 scopus 로고    scopus 로고
    • Chemokines in tumor development and progression
    • Mukaida N, Baba T. Chemokines in tumor development and progression. Exp Cell Res 2012; 317(5): 664-73.
    • (2012) Exp Cell Res , vol.317 , Issue.5 , pp. 664-673
    • Mukaida, N.1    Baba, T.2
  • 7
    • 42549172436 scopus 로고    scopus 로고
    • Interfering with chemokines and chemokine receptors as potential new therapeutic strategies
    • D'Elios MM, Del Prete G, Amedei A. Interfering with chemokines and chemokine receptors as potential new therapeutic strategies. Expert Opin Ther Pat 2008; 18(3): 309-25.
    • (2008) Expert Opin Ther Pat , vol.18 , Issue.3 , pp. 309-325
    • D'Elios, M.M.1    Del Prete, G.2    Amedei, A.3
  • 8
    • 34848855567 scopus 로고    scopus 로고
    • Less yin, more yang: Confronting the barriers to cancer immunotherapy
    • Lizée G, Cantu MA, Hwu P. Less yin, more yang: Confronting the barriers to cancer immunotherapy. Clin Cancer Res 2007; 13(18 Pt 1): 5250-5.
    • (2007) Clin Cancer Res , vol.13 , Issue.18 PART 1 , pp. 5250-5255
    • Lizée, G.1    Cantu, M.A.2    Hwu, P.3
  • 9
    • 53549087527 scopus 로고    scopus 로고
    • How tumours escape mass destruction
    • Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 2008; 27(45): 5894-903.
    • (2008) Oncogene , vol.27 , Issue.45 , pp. 5894-5903
    • Stewart, T.J.1    Abrams, S.I.2
  • 10
    • 0036852241 scopus 로고    scopus 로고
    • Cancer immunoediting: From immunosurveillance to tumor escape
    • Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 2002; 3(11): 991-8.
    • (2002) Nat Immunol , vol.3 , Issue.11 , pp. 991-998
    • Dunn, G.P.1    Bruce, A.T.2    Ikeda, H.3    Old, L.J.4    Schreiber, R.D.5
  • 11
    • 67649305234 scopus 로고    scopus 로고
    • New frontiers in cell-based immunotherapy of cancer
    • D'Elios MM, Del Prete G, Amedei A. New frontiers in cell-based immunotherapy of cancer. Expert Opin Ther Pat 2009; 19(5): 623-41.
    • (2009) Expert Opin Ther Pat , vol.19 , Issue.5 , pp. 623-641
    • D'Elios, M.M.1    Del Prete, G.2    Amedei, A.3
  • 12
    • 0020288361 scopus 로고
    • Interferon increases HLA synthesis in melanoma cells: Interferon-resistant and-sensitive cell lines
    • Basham TY, Bourgeade MF, Creasey AA, Merigan TC. Interferon increases HLA synthesis in melanoma cells: Interferon-resistant and-sensitive cell lines. Proc Natl Acad Sci USA 1982; 79(10): 3265-9.
    • (1982) Proc Natl Acad Sci USA , vol.79 , Issue.10 , pp. 3265-3269
    • Basham, T.Y.1    Bourgeade, M.F.2    Creasey, A.A.3    Merigan, T.C.4
  • 13
    • 61849134433 scopus 로고    scopus 로고
    • Addition of interferon-alpha to a standard maturation cocktail induces CD38 upregulation and increases dendritic cell function
    • Trepiakas R, Pedersen AE, Met O, Svane IM. Addition of interferon-alpha to a standard maturation cocktail induces CD38 upregulation and increases dendritic cell function. Vaccine 2009; 27(16): 2213-19.
    • (2009) Vaccine , vol.27 , Issue.16 , pp. 2213-2219
    • Trepiakas, R.1    Pedersen, A.E.2    Met, O.3    Svane, I.M.4
  • 14
    • 0033546053 scopus 로고    scopus 로고
    • The nature of the principal type 1 interferonproducing cells in human blood
    • Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferonproducing cells in human blood. Science 1999; 284(5421): 1835-7.
    • (1999) Science , vol.284 , Issue.5421 , pp. 1835-1837
    • Siegal, F.P.1    Kadowaki, N.2    Shodell, M.3    Fitzgerald-Bocarsly, P.A.4    Shah, K.5    Ho, S.6
  • 16
    • 34547099363 scopus 로고    scopus 로고
    • The interferons: 50 years after their discovery, there is much more to learn
    • Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007; 282(28): 20047-51.
    • (2007) J Biol Chem , vol.282 , Issue.28 , pp. 20047-20051
    • Pestka, S.1
  • 17
  • 18
    • 2942615257 scopus 로고    scopus 로고
    • The anti-angiogenic basis of metronomic chemotherapy
    • Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4(6): 423-36.
    • (2004) Nat Rev Cancer , vol.4 , Issue.6 , pp. 423-436
    • Kerbel, R.S.1    Kamen, B.A.2
  • 19
    • 0034088027 scopus 로고    scopus 로고
    • High-and low-dose interferon alfa-2b in highrisk melanoma: First analysis of intergroup trial e1690/s9111/c9190
    • Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in highrisk melanoma: First analysis of intergroup trial e1690/s9111/c9190. J Clin Oncol 2000; 18(12): 2444-58.
    • (2000) J Clin Oncol , vol.18 , Issue.12 , pp. 2444-2458
    • Kirkwood, J.M.1    Ibrahim, J.G.2    Sondak, V.K.3    Richards, J.4    Flaherty, L.E.5    Ernstoff, M.S.6
  • 20
    • 1842533233 scopus 로고    scopus 로고
    • A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma
    • Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10(5): 1670-7.
    • (2004) Clin Cancer Res , vol.10 , Issue.5 , pp. 1670-1677
    • Kirkwood, J.M.1    Manola, J.2    Ibrahim, J.3    Sondak, V.4    Ernstoff, M.S.5    Rao, U.6
  • 21
    • 0030030347 scopus 로고    scopus 로고
    • Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial est 1684
    • Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial est 1684. J Clin Oncol 1996; 14(1): 7-17.
    • (1996) J Clin Oncol , vol.14 , Issue.1 , pp. 7-17
    • Kirkwood, J.M.1    Strawderman, M.H.2    Ernstoff, M.S.3    Smith, T.J.4    Borden, E.C.5    Blum, R.H.6
  • 22
    • 77950576363 scopus 로고    scopus 로고
    • Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis
    • Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Nat Cancer Inst 2010; 102(7): 493-501.
    • (2010) J Nat Cancer Inst , vol.102 , Issue.7 , pp. 493-501
    • Mocellin, S.1    Pasquali, S.2    Rossi, C.R.3    Nitti, D.4
  • 23
    • 0022500725 scopus 로고
    • Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients
    • Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, et al. Alpha-2 interferon therapy of hairy-cell leukemia: A multicenter study of 64 patients. J Clin Oncol 1986; 4(6): 900-5.
    • (1986) J Clin Oncol , vol.4 , Issue.6 , pp. 900-905
    • Golomb, H.M.1    Jacobs, A.2    Fefer, A.3    Ozer, H.4    Thompson, J.5    Portlock, C.6
  • 24
    • 0022914303 scopus 로고
    • Alpha interferons in B-cell neoplasms
    • Quesada JR, Gutterman JU. Alpha interferons in B-cell neoplasms. Br J Haematol 1986; 64(4): 639-46.
    • (1986) Br J Haematol , vol.64 , Issue.4 , pp. 639-646
    • Quesada, J.R.1    Gutterman, J.U.2
  • 25
    • 0037362951 scopus 로고    scopus 로고
    • Extended follow-up of patients with hairy cell leukemia after treatment with cladribine
    • Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21(5): 891-6.
    • (2003) J Clin Oncol , vol.21 , Issue.5 , pp. 891-896
    • Goodman, G.R.1    Burian, C.2    Koziol, J.A.3    Saven, A.4
  • 27
    • 77954373338 scopus 로고    scopus 로고
    • Selective brafv600e inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
    • Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective brafv600e inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010; 70(13): 5213-9.
    • (2010) Cancer Res , vol.70 , Issue.13 , pp. 5213-5219
    • Boni, A.1    Cogdill, A.P.2    Dang, P.3    Udayakumar, D.4    Njauw, C.N.5    Sloss, C.M.6
  • 32
    • 4344710617 scopus 로고    scopus 로고
    • Regulation of gene expression by pegylated IFN-alpha2B and IFN-alpha2B in human peripheral blood mononuclear cells
    • Brassard DL, Delorenzo MM, Cox S, Leaman DW, Sun Y, Ding W, et al. Regulation of gene expression by pegylated IFN-alpha2B and IFN-alpha2B in human peripheral blood mononuclear cells. J Interferon Cytokine Res 2004; 24(8): 455-69.
    • (2004) J Interferon Cytokine Res , vol.24 , Issue.8 , pp. 455-469
    • Brassard, D.L.1    Delorenzo, M.M.2    Cox, S.3    Leaman, D.W.4    Sun, Y.5    Ding, W.6
  • 33
    • 67649933805 scopus 로고    scopus 로고
    • Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
    • Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: A phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2009; 27(18): 2916-23.
    • (2009) J Clin Oncol , vol.27 , Issue.18 , pp. 2916-2923
    • Bottomley, A.1    Coens, C.2    Suciu, S.3    Santinami, M.4    Kruit, W.5    Testori, A.6
  • 34
    • 84855982908 scopus 로고    scopus 로고
    • Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: Patients' and doctors' views
    • Loquai C, Schmidtmann I, Beutel M, Sunderkötter C, Grabbe S, Schiller M, et al. Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: Patients' and doctors' views. Eur J Dermatol 2011; 21(6): 976-84.
    • (2011) Eur J Dermatol , vol.21 , Issue.6 , pp. 976-984
    • Loquai, C.1    Schmidtmann, I.2    Beutel, M.3    Sunderkötter, C.4    Grabbe, S.5    Schiller, M.6
  • 35
    • 0036019503 scopus 로고    scopus 로고
    • Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner
    • Satomi H, Wang B, Fujisawa H, Otsuka F. Interferon-beta from melanoma cells suppresses the proliferations of melanoma cells in an autocrine manner. Cytokine 2002; 18(2): 108-15.
    • (2002) Cytokine , vol.18 , Issue.2 , pp. 108-115
    • Satomi, H.1    Wang, B.2    Fujisawa, H.3    Otsuka, F.4
  • 36
    • 0020377792 scopus 로고
    • Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells
    • Borden EC, Hogan TF, Voelkel JG. Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells. Cancer Res 1982; 42(12): 4948-53.
    • (1982) Cancer Res , vol.42 , Issue.12 , pp. 4948-4953
    • Borden, E.C.1    Hogan, T.F.2    Voelkel, J.G.3
  • 37
    • 0034895641 scopus 로고    scopus 로고
    • Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/Apo2l induction in melanoma cell lines
    • Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/Apo2l induction in melanoma cell lines. Clin Cancer Res 2001; 7(6): 1821-31.
    • (2001) Clin Cancer Res , vol.7 , Issue.6 , pp. 1821-1831
    • Chawla-Sarkar, M.1    Leaman, D.W.2    Borden, E.C.3
  • 39
    • 0023197097 scopus 로고
    • Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production
    • Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236(4804): 944-47.
    • (1987) Science , vol.236 , Issue.4804 , pp. 944-947
    • Snapper, C.M.1    Paul, W.E.2
  • 41
    • 0036645530 scopus 로고    scopus 로고
    • Suppression of lymphoma and epithelial malignancies effected by interferon gamma
    • Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med 2002; 196(1): 129-34.
    • (2002) J Exp Med , vol.196 , Issue.1 , pp. 129-134
    • Street, S.E.1    Trapani, J.A.2    McGregor, D.3    Smyth, M.J.4
  • 42
    • 17344383269 scopus 로고    scopus 로고
    • Tumor cell responses to IFN gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
    • Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, et al. Tumor cell responses to IFN gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9(1): 25-34.
    • (1998) Immunity , vol.9 , Issue.1 , pp. 25-34
    • Coughlin, C.M.1    Salhany, K.E.2    Gee, M.S.3    LaTemple, D.C.4    Kotenko, S.5    Ma, X.6
  • 43
    • 0023118633 scopus 로고
    • Inhibition of endothelial cell proliferation by gamma-interferon
    • Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104(3): 689-96.
    • (1987) J Cell Biol , vol.104 , Issue.3 , pp. 689-696
    • Friesel, R.1    Komoriya, A.2    McIag, T.3
  • 44
    • 0033775561 scopus 로고    scopus 로고
    • Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian urologic oncology group
    • Elhilali MM, Gleave M, Fradet Y, Davis I, Venner P, Saad F, et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian urologic oncology group. BJU Int 2000; 86(6): 613-8.
    • (2000) BJU Int , vol.86 , Issue.6 , pp. 613-618
    • Elhilali, M.M.1    Gleave, M.2    Fradet, Y.3    Davis, I.4    Venner, P.5    Saad, F.6
  • 45
    • 0036375296 scopus 로고    scopus 로고
    • Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation
    • Koziner B, Dengra C, Cisneros M, Glancszpigel R. Double-blind prospective randomized comparison of interferon gamma-1b versus placebo after autologous stem cell transplantation. Acta Haematol 2002; 108(2): 66-73.
    • (2002) Acta Haematol , vol.108 , Issue.2 , pp. 66-73
    • Koziner, B.1    Dengra, C.2    Cisneros, M.3    Glancszpigel, R.4
  • 46
    • 0037232131 scopus 로고    scopus 로고
    • Novel interferons
    • Vilcek, J. Novel interferons. Nat Immunol 2003; 4(1): 8-9.
    • (2003) Nat Immunol , vol.4 , Issue.1 , pp. 8-9
    • Vilcek, J.1
  • 48
    • 77955886364 scopus 로고    scopus 로고
    • Interferon-lambda as a potential therapeutic agent in cancer treatment
    • Steen HC, Gamero AM. Interferon-lambda as a potential therapeutic agent in cancer treatment. J Interferon Cytokine Res 2010; 30(8): 597-602.
    • (2010) J Interferon Cytokine Res , vol.30 , Issue.8 , pp. 597-602
    • Steen, H.C.1    Gamero, A.M.2
  • 50
    • 0024391574 scopus 로고
    • Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation
    • Voss SD, Hank JA, Nobis CA, Fisch P, Sosman JA, Sondel PM. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 1989; 29(4): 261-9.
    • (1989) Cancer Immunol Immunother , vol.29 , Issue.4 , pp. 261-269
    • Voss, S.D.1    Hank, J.A.2    Nobis, C.A.3    Fisch, P.4    Sosman, J.A.5    Sondel, P.M.6
  • 51
    • 0034716925 scopus 로고    scopus 로고
    • Regulatory t cells: Key controllers of immunologic self-tolerance
    • Sakaguchi S. Regulatory t cells: Key controllers of immunologic self-tolerance. Cell 2000; 101(5): 455.
    • (2000) Cell , vol.101 , Issue.5 , pp. 455
    • Sakaguchi, S.1
  • 54
    • 0036276002 scopus 로고    scopus 로고
    • Interleukin-2: Clinical applications
    • Atkins MB. Interleukin-2: Clinical applications. Semin Oncol 2002; 29(3 Suppl 7): 12-17.
    • (2002) Semin Oncol , vol.29 , Issue.3 SUPPL. 7 , pp. 12-17
    • Atkins, M.B.1
  • 55
    • 0033847587 scopus 로고    scopus 로고
    • Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma
    • Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6(Suppl 1): S55-S7.
    • (2000) Cancer J Sci Am , vol.6 , Issue.SUPPL. 1
    • Fisher, R.I.1    Rosenberg, S.A.2    Fyfe, G.3
  • 56
    • 0028060152 scopus 로고
    • A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice
    • Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994; 91(20): 9626-30.
    • (1994) Proc Natl Acad Sci USA , vol.91 , Issue.20 , pp. 9626-9630
    • Sabzevari, H.1    Gillies, S.D.2    Mueller, B.M.3    Pancook, J.D.4    Reisfeld, R.A.5
  • 57
    • 0034896595 scopus 로고    scopus 로고
    • Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy
    • Christ O, Seiter S, Matzku S, Burger C, Zöller M. Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy. Clin Cancer Res 2001; 7(4): 985-98.
    • (2001) Clin Cancer Res , vol.7 , Issue.4 , pp. 985-998
    • Christ, O.1    Seiter, S.2    Matzku, S.3    Burger, C.4    Zöller, M.5
  • 59
    • 70349439274 scopus 로고    scopus 로고
    • Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma
    • Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, et al. Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res 2009; 15(18): 5923-30.
    • (2009) Clin Cancer Res , vol.15 , Issue.18 , pp. 5923-5930
    • Hank, J.A.1    Gan, J.2    Ryu, H.3    Ostendorf, A.4    Stauder, M.C.5    Sternberg, A.6
  • 60
    • 67650442052 scopus 로고    scopus 로고
    • The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma
    • Yamane BH, Hank JA, Albertini MR, Sondel PM. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs 2009; 18(7): 991-1000.
    • (2009) Expert Opin Investig Drugs , vol.18 , Issue.7 , pp. 991-1000
    • Yamane, B.H.1    Hank, J.A.2    Albertini, M.R.3    Sondel, P.M.4
  • 61
    • 0031740732 scopus 로고    scopus 로고
    • Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency
    • Puel A, Ziegler SF, Buckley RH, Leonard WJ. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998; 20(4): 394-39.
    • (1998) Nat Genet , vol.20 , Issue.4 , pp. 339-394
    • Puel, A.1    Ziegler, S.F.2    Buckley, R.H.3    Leonard, W.J.4
  • 62
    • 0034332403 scopus 로고    scopus 로고
    • Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo
    • Schluns KS, Kieper WC, Jameson SC, Lefrançois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000; 1(5): 426-32.
    • (2000) Nat Immunol , vol.1 , Issue.5 , pp. 426-432
    • Schluns, K.S.1    Kieper, W.C.2    Jameson, S.C.3    Lefrançois, L.4
  • 65
    • 69249230925 scopus 로고    scopus 로고
    • + T-cell responses after immunization with recombinant lentivector
    • + T-cell responses after immunization with recombinant lentivector. Blood 2009; 113(26): 6629-37.
    • (2009) Blood , vol.113 , Issue.26 , pp. 6629-6637
    • Colombetti, S.1    Lévy, F.2    Chapatte, L.3
  • 66
    • 79955418828 scopus 로고    scopus 로고
    • Harnessing the biology of IL-7 for therapeutic application
    • Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11(5): 330-42.
    • (2011) Nat Rev Immunol , vol.11 , Issue.5 , pp. 330-342
    • McKall, C.L.1    Fry, T.J.2    Gress, R.E.3
  • 68
    • 84055199517 scopus 로고    scopus 로고
    • Cytokines in cancer immunotherapy
    • Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers 2011; 3: 3856-93.
    • (2011) Cancers , vol.3 , pp. 3856-3893
    • Lee, S.1    Margolin, K.2
  • 69
    • 33646580769 scopus 로고    scopus 로고
    • The structure of the interleukin-15 alpha receptor and its implications for ligand binding
    • Lorenzen I, Dingley AJ, Jacques Y, Grötzinger J. The structure of the interleukin-15 alpha receptor and its implications for ligand binding. J Biol Chem 2006; 281(10): 6642-7.
    • (2006) J Biol Chem , vol.281 , Issue.10 , pp. 6642-6647
    • Lorenzen, I.1    Dingley, A.J.2    Jacques, Y.3    Grötzinger, J.4
  • 72
    • 0034665093 scopus 로고    scopus 로고
    • The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement
    • Di Carlo E, Comes A, Basso S, De Ambrosis A, Meazza R, Musiani P, et al. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 2000; 165(6): 3111-8.
    • (2000) J Immunol , vol.165 , Issue.6 , pp. 3111-3118
    • Di Carlo, E.1    Comes, A.2    Basso, S.3    de Ambrosis, A.4    Meazza, R.5    Musiani, P.6
  • 73
    • 4444240035 scopus 로고    scopus 로고
    • Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokineactivated killer cells in celiac disease
    • Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokineactivated killer cells in celiac disease. Immunity 2004; 21(3): 357-66.
    • (2004) Immunity , vol.21 , Issue.3 , pp. 357-366
    • Meresse, B.1    Chen, Z.2    Ciszewski, C.3    Tretiakova, M.4    Bhagat, G.5    Krausz, T.N.6
  • 74
    • 0346995205 scopus 로고    scopus 로고
    • IL-21: A novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses
    • Habib T, Nelson A, Kaushansky K. IL-21: A novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol 2003; 112(6): 1033-45.
    • (2003) J Allergy Clin Immunol , vol.112 , Issue.6 , pp. 1033-1045
    • Habib, T.1    Nelson, A.2    Kaushansky, K.3
  • 75
    • 2542565699 scopus 로고    scopus 로고
    • Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated antitumour responses
    • Sivakumar PV, Foster DC, Clegg CH. Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated antitumour responses. Immunology 2004; 112(2): 177-82.
    • (2004) Immunology , vol.112 , Issue.2 , pp. 177-182
    • Sivakumar, P.V.1    Foster, D.C.2    Clegg, C.H.3
  • 77
    • 33746088835 scopus 로고    scopus 로고
    • Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model
    • He H, Wisner P, Yang G, Hu HM, Haley D, Miller W, et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 2006; 4: 24.
    • (2006) J Transl Med , vol.4 , pp. 24
    • He, H.1    Wisner, P.2    Yang, G.3    Hu, H.M.4    Haley, D.5    Miller, W.6
  • 78
    • 33745139171 scopus 로고    scopus 로고
    • Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma
    • Curti BD. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev Anticancer Ther 2006; 6(6): 905-9.
    • (2006) Expert Rev Anticancer Ther , vol.6 , Issue.6 , pp. 905-909
    • Curti, B.D.1
  • 79
    • 0347320749 scopus 로고    scopus 로고
    • In vivo antitumor activity of interleukin 21 mediated by natural killer cells
    • Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, Feng C, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003; 63(24): 9016-22.
    • (2003) Cancer Res , vol.63 , Issue.24 , pp. 9016-9022
    • Wang, G.1    Tschoi, M.2    Spolski, R.3    Lou, Y.4    Ozaki, K.5    Feng, C.6
  • 80
    • 10744230081 scopus 로고    scopus 로고
    • Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma
    • Kishida T, Asada H, Itokawa Y, Cui FD, Shin-Ya M, Gojo S, et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol Ther 2003; 8(4): 552-8.
    • (2003) Mol Ther , vol.8 , Issue.4 , pp. 552-558
    • Kishida, T.1    Asada, H.2    Itokawa, Y.3    Cui, F.D.4    Shin-Ya, M.5    Gojo, S.6
  • 81
    • 23444445913 scopus 로고    scopus 로고
    • IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response
    • Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005; 175(4): 2261-9.
    • (2005) J Immunol , vol.175 , Issue.4 , pp. 2261-2269
    • Li, Y.1    Bleakley, M.2    Yee, C.3
  • 82
    • 0142250392 scopus 로고    scopus 로고
    • Targeted antiinterleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence
    • Trikha M, Corringham R, Klein B, Rossi JF. Targeted antiinterleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003; 9(13): 4653-65.
    • (2003) Clin Cancer Res , vol.9 , Issue.13 , pp. 4653-4665
    • Trikha, M.1    Corringham, R.2    Klein, B.3    Rossi, J.F.4
  • 83
    • 0031811798 scopus 로고    scopus 로고
    • Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study
    • van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study. Brit J Haematol 1998; 102(3): 783-90.
    • (1998) Brit J Haematol , vol.102 , Issue.3 , pp. 783-790
    • van Zaanen, H.C.1    Lokhorst, H.M.2    Aarden, L.A.3    Rensink, H.J.4    Warnaar, S.O.5    van der Lelie, J.6
  • 84
    • 0030796001 scopus 로고    scopus 로고
    • Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma
    • Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72(3): 424-30.
    • (1997) Int J Cancer , vol.72 , Issue.3 , pp. 424-430
    • Blay, J.Y.1    Rossi, J.F.2    Wijdenes, J.3    Menetrier-Caux, C.4    Schemann, S.5    Négrier, S.6
  • 85
    • 0026591094 scopus 로고
    • Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients
    • Chehimi J, Starr SE, Frank I, Rengaraju M, Jackson SJ, Llanes C, et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175(3): 789-96.
    • (1992) J Exp Med , vol.175 , Issue.3 , pp. 789-796
    • Chehimi, J.1    Starr, S.E.2    Frank, I.3    Rengaraju, M.4    Jackson, S.J.5    Llanes, C.6
  • 86
    • 13444249480 scopus 로고    scopus 로고
    • Synergistic effects of IL-12 and IL-18 in skewing tumorreactive T-cell responses towards a type 1 pattern
    • Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, et al. Synergistic effects of IL-12 and IL-18 in skewing tumorreactive T-cell responses towards a type 1 pattern. Cancer Res 2005; 65(3): 1063-70.
    • (2005) Cancer Res , vol.65 , Issue.3 , pp. 1063-1070
    • Li, Q.1    Carr, A.L.2    Donald, E.J.3    Skitzki, J.J.4    Okuyama, R.5    Stoolman, L.M.6
  • 87
    • 0037086632 scopus 로고    scopus 로고
    • Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity
    • Kaufman HL, Flanagan K, Lee CS, Perretta DJ, Horig H. Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine 2002; 20(13-14): 1862-9.
    • (2002) Vaccine , vol.20 , Issue.13-14 , pp. 1862-1869
    • Kaufman, H.L.1    Flanagan, K.2    Lee, C.S.3    Perretta, D.J.4    Horig, H.5
  • 89
    • 0034103809 scopus 로고    scopus 로고
    • Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response
    • Gollob JA, Mier JW, Veenstra K, McDermott DF, Clancy D, Clancy M, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: Ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res 2000; 6(5): 1678-92.
    • (2000) Clin Cancer Res , vol.6 , Issue.5 , pp. 1678-1692
    • Gollob, J.A.1    Mier, J.W.2    Veenstra, K.3    McDermott, D.F.4    Clancy, D.5    Clancy, M.6
  • 90
    • 58049200809 scopus 로고    scopus 로고
    • Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
    • Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26(36): 5896-903.
    • (2008) J Clin Oncol , vol.26 , Issue.36 , pp. 5896-5903
    • Daud, A.I.1    DeConti, R.C.2    Andrews, S.3    Urbas, P.4    Riker, A.I.5    Sondak, V.K.6
  • 91
    • 15444347156 scopus 로고    scopus 로고
    • A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3-cells
    • Tomura M, Zhou XY, Maruo S, Ahn HJ, Hamaoka T, Okamura H, et al. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3-cells. J Immunol 1998; 160(10): 4738-46.
    • (1998) J Immunol , vol.160 , Issue.10 , pp. 4738-4746
    • Tomura, M.1    Zhou, X.Y.2    Maruo, S.3    Ahn, H.J.4    Hamaoka, T.5    Okamura, H.6
  • 92
    • 0032522801 scopus 로고    scopus 로고
    • -T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18
    • -T cell subsets to express IL-18 receptor and produce IFN-gamma in response to IL-18. J Immunol 1998; 160(8): 3759-65.
    • (1998) J Immunol , vol.160 , Issue.8 , pp. 3759-3765
    • Tomura, M.1    Maruo, S.2    Mu, J.3    Zhou, X.Y.4    Ahn, H.J.5    Hamaoka, T.6
  • 97
    • 0141956433 scopus 로고    scopus 로고
    • Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF
    • Martinez-Moczygemba M, Huston DP. Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol 2003; 112(4): 653-65.
    • (2003) J Allergy Clin Immunol , vol.112 , Issue.4 , pp. 653-665
    • Martinez-Moczygemba, M.1    Huston, D.P.2
  • 98
    • 0027538181 scopus 로고
    • Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
    • Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90(8): 3539-43.
    • (1993) Proc Natl Acad Sci USA , vol.90 , Issue.8 , pp. 3539-3543
    • Dranoff, G.1    Jaffee, E.2    Lazenby, A.3    Golumbek, P.4    Levitsky, H.5    Brose, K.6
  • 99
  • 100
    • 0032809320 scopus 로고    scopus 로고
    • Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor
    • Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 1999; 5(7): 1738-44.
    • (1999) Clin Cancer Res , vol.5 , Issue.7 , pp. 1738-1744
    • Small, E.J.1    Reese, D.M.2    Um, B.3    Whisenant, S.4    Dixon, S.C.5    Figg, W.D.6
  • 101
    • 0022478367 scopus 로고
    • Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
    • Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986; 232(4749): 506-8.
    • (1986) Science , vol.232 , Issue.4749 , pp. 506-508
    • Grabstein, K.H.1    Urdal, D.L.2    Tushinski, R.J.3    Mochizuki, D.Y.4    Price, V.L.5    Cantrell, M.A.6
  • 103
    • 34447121852 scopus 로고    scopus 로고
    • MFG-E8-mediated uptake of apoptotic cells by APCs links the pro-and antiinflammatory activities of GMCSF
    • Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro-and antiinflammatory activities of GMCSF. J Clin Invest 2007; 117(7): 1902-13.
    • (2007) J Clin Invest , vol.117 , Issue.7 , pp. 1902-1913
    • Jinushi, M.1    Nakazaki, Y.2    Dougan, M.3    Carrasco, D.R.4    Mihm, M.5    Dranoff, G.6
  • 104
    • 0034807621 scopus 로고    scopus 로고
    • Intralesional granulocyte-monocyte colonystimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: A pilot study in elderly patients
    • Ridolfi L, Ridolfi R, Ascari-Raccagni A, Fabbri M, Casadei S, Gatti A, et al. Intralesional granulocyte-monocyte colonystimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: A pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001; 15(3): 218-23.
    • (2001) J Eur Acad Dermatol Venereol , vol.15 , Issue.3 , pp. 218-223
    • Ridolfi, L.1    Ridolfi, R.2    Ascari-Raccagni, A.3    Fabbri, M.4    Casadei, S.5    Gatti, A.6
  • 105
    • 0038793763 scopus 로고    scopus 로고
    • GM-CSF-secreting melanoma vaccines
    • Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22(20): 3188-92.
    • (2003) Oncogene , vol.22 , Issue.20 , pp. 3188-3192
    • Dranoff, G.1
  • 106
    • 33845336115 scopus 로고    scopus 로고
    • A phase I study of OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
    • Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12(22): 6737-47.
    • (2006) Clin Cancer Res , vol.12 , Issue.22 , pp. 6737-6747
    • Hu, J.C.1    Coffin, R.S.2    Davis, C.J.3    Graham, N.J.4    Groves, N.5    Guest, P.J.6
  • 107
    • 73349133717 scopus 로고    scopus 로고
    • Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpes virus in patients with unresectable metastatic melanoma
    • Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpes virus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27(34): 5763-71.
    • (2009) J Clin Oncol , vol.27 , Issue.34 , pp. 5763-5771
    • Senzer, N.N.1    Kaufman, H.L.2    Amatruda, T.3    Nemunaitis, M.4    Reid, T.5    Daniels, G.6
  • 108
    • 77149141965 scopus 로고    scopus 로고
    • Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma
    • Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17(3): 718-30.
    • (2010) Ann Surg Oncol , vol.17 , Issue.3 , pp. 718-730
    • Kaufman, H.L.1    Kim, D.W.2    DeRaffele, G.3    Mitcham, J.4    Coffin, R.S.5    Kim-Schulze, S.6
  • 109
    • 77957253429 scopus 로고    scopus 로고
    • Optim trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
    • Kaufman HL, Bines SD. Optim trial: A phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6(6): 941-9.
    • (2010) Future Oncol , vol.6 , Issue.6 , pp. 941-949
    • Kaufman, H.L.1    Bines, S.D.2
  • 110
    • 77958006456 scopus 로고    scopus 로고
    • Cellular vaccine approaches
    • Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J 2010; 16(4): 304-10.
    • (2010) Cancer J , vol.16 , Issue.4 , pp. 304-310
    • Le, D.T.1    Pardoll, D.M.2    Jaffee, E.M.3
  • 111
    • 41149108216 scopus 로고    scopus 로고
    • Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines
    • Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 2008; 222: 287-98.
    • (2008) Immunol Rev , vol.222 , pp. 287-298
    • Jinushi, M.1    Hodi, F.S.2    Dranoff, G.3
  • 112
    • 0141576738 scopus 로고    scopus 로고
    • Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
    • Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21(17): 3343-50.
    • (2003) J Clin Oncol , vol.21 , Issue.17 , pp. 3343-3350
    • Soiffer, R.1    Hodi, F.S.2    Haluska, F.3    Jung, K.4    Gillessen, S.5    Singer, S.6
  • 113
    • 0642311904 scopus 로고    scopus 로고
    • Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells
    • Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colonystimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21(21): 4016-26.
    • (2003) J Clin Oncol , vol.21 , Issue.21 , pp. 4016-4026
    • Slingluff Jr., C.L.1    Petroni, G.R.2    Yamshchikov, G.V.3    Barnd, D.L.4    Eastham, S.5    Galavotti, H.6
  • 116
    • 0034080318 scopus 로고    scopus 로고
    • The biology of chemokines and their receptors
    • Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18: 217-42.
    • (2000) Annu Rev Immunol , vol.18 , pp. 217-242
    • Rossi, D.1    Zlotnik, A.2
  • 117
    • 0034829818 scopus 로고    scopus 로고
    • Chemokines in pathology and medicine
    • Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001; 250(2): 91-104.
    • (2001) J Intern Med , vol.250 , Issue.2 , pp. 91-104
    • Baggiolini, M.1
  • 118
    • 3042822267 scopus 로고    scopus 로고
    • Cancer and the chemokine network
    • Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4(7): 540-50.
    • (2004) Nat Rev Cancer , vol.4 , Issue.7 , pp. 540-550
    • Balkwill, F.1
  • 119
    • 0033214348 scopus 로고    scopus 로고
    • CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs
    • Förster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, Wolf E, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 1999; 99(1): 23-33.
    • (1999) Cell , vol.99 , Issue.1 , pp. 23-33
    • Förster, R.1    Schubel, A.2    Breitfeld, D.3    Kremmer, E.4    Renner-Müller, I.5    Wolf, E.6
  • 120
    • 0142166426 scopus 로고    scopus 로고
    • Chemokines. Agents for the immunotherapy of cancer?
    • Homey B, Müller A, Zlotnik A. Chemokines. Agents for the immunotherapy of cancer? Nat Rev Immunol 2002; 2(3): 175-84.
    • (2002) Nat Rev Immunol , vol.2 , Issue.3 , pp. 175-184
    • Homey, B.1    Müller, A.2    Zlotnik, A.3
  • 121
    • 0034192078 scopus 로고    scopus 로고
    • Secondary lymphoid tissue chemokine mediates T celldependent antitumor responses in vivo
    • Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, et al. Secondary lymphoid tissue chemokine mediates T celldependent antitumor responses in vivo. J Immunol 2000; 164(9): 4558-63.
    • (2000) J Immunol , vol.164 , Issue.9 , pp. 4558-4563
    • Sharma, S.1    Stolina, M.2    Luo, J.3    Strieter, R.M.4    Burdick, M.5    Zhu, L.X.6
  • 122
    • 0034663955 scopus 로고    scopus 로고
    • Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms
    • Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000; 165(4): 1992-2000.
    • (2000) J Immunol , vol.165 , Issue.4 , pp. 1992-2000
    • Vicari, A.P.1    Ait-Yahia, S.2    Chemin, K.3    Mueller, A.4    Zlotnik, A.5    Caux, C.6
  • 123
    • 0034655163 scopus 로고    scopus 로고
    • CC chemokine CK b-11/MIP-3 b /ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells
    • Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, et al. CC chemokine CK b-11/MIP-3 b /ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000; 164(8): 3200-06.
    • (2000) J Immunol , vol.164 , Issue.8 , pp. 3200-3206
    • Braun, S.E.1    Chen, K.2    Foster, R.G.3    Kim, C.H.4    Hromas, R.5    Kaplan, M.H.6
  • 125
    • 0035266293 scopus 로고    scopus 로고
    • T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy
    • Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, et al. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: Augmentation of dendritic cell-based immunotherapy. Cancer Res 2001; 61(5): 2062-70.
    • (2001) Cancer Res , vol.61 , Issue.5 , pp. 2062-2070
    • Kirk, C.J.1    Hartigan-O'Connor, D.2    Nickoloff, B.J.3    Chamberlain, J.S.4    Giedlin, M.5    Aukerman, L.6
  • 126
    • 0035893749 scopus 로고    scopus 로고
    • The dynamics of the Tcell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally
    • Kirk CJ, Hartigan-O'Connor D, Mulé JJ. The dynamics of the Tcell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res 2001; 61(24): 8794-802.
    • (2001) Cancer Res , vol.61 , Issue.24 , pp. 8794-8802
    • Kirk, C.J.1    Hartigan-O'Connor, D.2    Mulé, J.J.3
  • 128
    • 77957973787 scopus 로고    scopus 로고
    • Chemokines: Can effector cells be redirected to the site of the tumor?
    • Dubinett SM, Lee JM, Sharma S, Mulé JJ. Chemokines: Can effector cells be redirected to the site of the tumor? Cancer J 2010; 16(4): 325-35.
    • (2010) Cancer J , vol.16 , Issue.4 , pp. 325-335
    • Dubinett, S.M.1    Lee, J.M.2    Sharma, S.3    Mulé, J.J.4
  • 129
    • 49649091143 scopus 로고    scopus 로고
    • Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a Phase I trial in nonsmall cell lung cancer
    • Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, et al. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a Phase I trial in nonsmall cell lung cancer. J Trans Med 2008; 6: 38.
    • (2008) J Trans Med , vol.6 , pp. 38
    • Baratelli, F.1    Takedatsu, H.2    Hazra, S.3    Peebles, K.4    Luo, J.5    Kurimoto, P.S.6
  • 131
    • 44349100383 scopus 로고    scopus 로고
    • Organ selectivity in metastasis: Regulation by chemokines and their receptors
    • Ben-Baruch A. Organ selectivity in metastasis: Regulation by chemokines and their receptors. Clin Exp Metast 2008; 25(4). 345-56.
    • (2008) Clin Exp Metast , vol.25 , Issue.4 , pp. 345-356
    • Ben-Baruch, A.1
  • 132
    • 0035824083 scopus 로고    scopus 로고
    • Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma
    • Wiley HE, Gonzalez EB, Maki W, Wu MT, Hwang ST. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 2001; 93(21): 1638-43.
    • (2001) J Natl Cancer Inst , vol.93 , Issue.21 , pp. 1638-1643
    • Wiley, H.E.1    Gonzalez, E.B.2    Maki, W.3    Wu, M.T.4    Hwang, S.T.5
  • 134
    • 54249152886 scopus 로고    scopus 로고
    • CCR7 regulates B16 murine melanoma cell tumorigenesis in skin
    • Fang L, Lee VC, Cha E, Zhang H, Hwang ST. CCR7 regulates B16 murine melanoma cell tumorigenesis in skin. J Leukoc Biol 2008; 84(4): 965-72.
    • (2008) J Leukoc Biol , vol.84 , Issue.4 , pp. 965-972
    • Fang, L.1    Lee, V.C.2    Cha, E.3    Zhang, H.4    Hwang, S.T.5
  • 135
    • 0035282432 scopus 로고    scopus 로고
    • Involvement of chemokine receptors in breast cancer metastasis
    • Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410(6824): 50-6.
    • (2001) Nature , vol.410 , Issue.6824 , pp. 50-56
    • Müller, A.1    Homey, B.2    Soto, H.3    Ge, N.4    Catron, D.5    Buchanan, M.E.6
  • 136
    • 33846229266 scopus 로고    scopus 로고
    • Endothelins induce Ccr7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1
    • Wilson JL, Burchell J, Grimshaw MJ. Endothelins induce Ccr7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. Cancer Res 2006; 66(24): 11802-7.
    • (2006) Cancer Res , vol.66 , Issue.24 , pp. 11802-11807
    • Wilson, J.L.1    Burchell, J.2    Grimshaw, M.J.3
  • 137
    • 67649249962 scopus 로고    scopus 로고
    • Ccr7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia
    • Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG, et al. Ccr7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 2009; 459(7249): 1000-4.
    • (2009) Nature , vol.459 , Issue.7249 , pp. 1000-1004
    • Buonamici, S.1    Trimarchi, T.2    Ruocco, M.G.3    Reavie, L.4    Cathelin, S.5    Mar, B.G.6
  • 138
    • 33750313449 scopus 로고    scopus 로고
    • CC-chemokine ligand 16 induces a novel maturation program in human immature monocyte-derived dendritic cells
    • Cappello P, Fraone T, Barberis L, Costa C, Hirsch E, Elia AR, et al. CC-chemokine ligand 16 induces a novel maturation program in human immature monocyte-derived dendritic cells. J Immunol 2006; 177(9): 6143-51.
    • (2006) J Immunol , vol.177 , Issue.9 , pp. 6143-6151
    • Cappello, P.1    Fraone, T.2    Barberis, L.3    Costa, C.4    Hirsch, E.5    Elia, A.R.6
  • 139
    • 0034254357 scopus 로고    scopus 로고
    • LEC induces chemotaxis and adhension by interacting with CCR1 and CCR8
    • Howard OMZ, Dong HF, Shirakawa AK, Oppenheim JJ. LEC induces chemotaxis and adhension by interacting with CCR1 and CCR8. Blood 2000; 96(3): 840-5.
    • (2000) Blood , vol.96 , Issue.3 , pp. 840-845
    • Howard, O.M.Z.1    Dong, H.F.2    Shirakawa, A.K.3    Oppenheim, J.J.4
  • 140
    • 0034653473 scopus 로고    scopus 로고
    • Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with and impressive recruitment of APCs, lymphocytes, and granulocytes
    • Giovarelli M, Cappello P, Forni G, Salcedo T, Moore PA, LeFleur DW, et al. Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with and impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol 2000; 164(6): 3200-6.
    • (2000) J Immunol , vol.164 , Issue.6 , pp. 3200-3206
    • Giovarelli, M.1    Cappello, P.2    Forni, G.3    Salcedo, T.4    Moore, P.A.5    LeFleur, D.W.6
  • 143
    • 0346995283 scopus 로고    scopus 로고
    • Complete regression of experimental solid tumors by combination LEC-chTNT-3 immunotherapy and CD25(+) T-cell depletion
    • Li J, Hu P, Khawli LA, Epstein AL. Complete regression of experimental solid tumors by combination LEC-chTNT-3 immunotherapy and CD25(+) T-cell depletion. Cancer Res 2003; 63(23): 8384-92.
    • (2003) Cancer Res , vol.63 , Issue.23 , pp. 8384-8392
    • Li, J.1    Hu, P.2    Khawli, L.A.3    Epstein, A.L.4
  • 144
    • 77951109790 scopus 로고    scopus 로고
    • CCL5 as an adjuvant for cancer immunotherapy
    • Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Exp Opin Biol Ther 2010; 10(5): 725-33.
    • (2010) Exp Opin Biol Ther , vol.10 , Issue.5 , pp. 725-733
    • Lapteva, N.1    Huang, X.F.2
  • 146
    • 47749097074 scopus 로고    scopus 로고
    • The inflammatory chemokines CCL2 and CCL5 in breast cancer
    • Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 2008; 267(2): 271-85.
    • (2008) Cancer Lett , vol.267 , Issue.2 , pp. 271-285
    • Soria, G.1    Ben-Baruch, A.2
  • 147
    • 33745362968 scopus 로고    scopus 로고
    • T regulatory cells and migration
    • Chen D, Bromberg JS. T regulatory cells and migration. Am J Trans 2006; 6(7): 1518-23.
    • (2006) Am J Trans , vol.6 , Issue.7 , pp. 1518-1523
    • Chen, D.1    Bromberg, J.S.2
  • 148
    • 47949090079 scopus 로고    scopus 로고
    • The role of myeloid cells in the promotion of tumour angiogenesis
    • Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8(8): 618-31.
    • (2008) Nat Rev Cancer , vol.8 , Issue.8 , pp. 618-631
    • Murdoch, C.1    Muthana, M.2    Coffelt, S.B.3    Lewis, C.E.4
  • 150
    • 77951631347 scopus 로고    scopus 로고
    • Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth
    • Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010; 102(8): 522-8.
    • (2010) J Natl Cancer Inst , vol.102 , Issue.8 , pp. 522-528
    • Zhang, J.1    Lu, Y.2    Pienta, K.J.3
  • 151
    • 15744364923 scopus 로고    scopus 로고
    • Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12
    • Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ, Markert JM. Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther 2005; 12(4): 359-68.
    • (2005) Cancer Gene Ther , vol.12 , Issue.4 , pp. 359-368
    • Parker, J.N.1    Meleth, S.2    Hughes, K.B.3    Gillespie, G.Y.4    Whitley, R.J.5    Markert, J.M.6
  • 152
    • 0035102199 scopus 로고    scopus 로고
    • Vaccination with MCP-1 cDNA transfectant on human malignant glioma in nude mice induces migration of monocytes and NK cells to the tumor
    • Nagai M, Masuzawa T. Vaccination with MCP-1 cDNA transfectant on human malignant glioma in nude mice induces migration of monocytes and NK cells to the tumor. Int Immunopharmacol 2001; 1(4): 657-64.
    • (2001) Int Immunopharmacol , vol.1 , Issue.4 , pp. 657-664
    • Nagai, M.1    Masuzawa, T.2
  • 153
    • 0029103127 scopus 로고
    • Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration
    • Hirose K, Hakozaki M, Nyunoya Y, Kobayashi Y, Matsushita K, Takenouchi T, et al. Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer 1995; 72(3): 708-14.
    • (1995) Br J Cancer , vol.72 , Issue.3 , pp. 708-714
    • Hirose, K.1    Hakozaki, M.2    Nyunoya, Y.3    Kobayashi, Y.4    Matsushita, K.5    Takenouchi, T.6
  • 154
    • 77953610370 scopus 로고    scopus 로고
    • Therapeutic effect of MIP-1a-recruited dendritic cells on preestablished solid and metastatic tumors
    • Cao Q, Jin Y, Jin M, He S, Gu Q, He S, et al. Therapeutic effect of MIP-1a-recruited dendritic cells on preestablished solid and metastatic tumors. Cancer Lett 2010; 295(1): 17-26.
    • (2010) Cancer Lett , vol.295 , Issue.1 , pp. 17-26
    • Cao, Q.1    Jin, Y.2    Jin, M.3    He, S.4    Gu, Q.5    He, S.6
  • 155
    • 70449706176 scopus 로고    scopus 로고
    • Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma
    • Aravindaram K, Yu HH, Lan CW, Wang PH, Chen YH, Chen HM, et al. Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma. Gene Ther 2009; 16(11): 1329-39.
    • (2009) Gene Ther , vol.16 , Issue.11 , pp. 1329-1339
    • Aravindaram, K.1    Yu, H.H.2    Lan, C.W.3    Wang, P.H.4    Chen, Y.H.5    Chen, H.M.6
  • 156
    • 45849101661 scopus 로고    scopus 로고
    • TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model
    • Inoue H, Iga M, Xin M, Asahi S, Nakamura T, Kurita R, et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother 2008; 57(9): 1399-411.
    • (2008) Cancer Immunol Immunother , vol.57 , Issue.9 , pp. 1399-1411
    • Inoue, H.1    Iga, M.2    Xin, M.3    Asahi, S.4    Nakamura, T.5    Kurita, R.6
  • 157
    • 58549085171 scopus 로고    scopus 로고
    • Vaccination with combination of Fit3L and RANTES in a DNA primeprotein boost regimen elicits strong cell-mediated immunity and antitumor effect
    • Song S, Liu C, Wang J, Zhang Y, You H, Wang Y, et al. Vaccination with combination of Fit3L and RANTES in a DNA primeprotein boost regimen elicits strong cell-mediated immunity and antitumor effect. Vaccine 2009; 27(7): 1111-8.
    • (2009) Vaccine , vol.27 , Issue.7 , pp. 1111-1118
    • Song, S.1    Liu, C.2    Wang, J.3    Zhang, Y.4    You, H.5    Wang, Y.6
  • 159
    • 77957157551 scopus 로고    scopus 로고
    • The multiple faces of CXCL12 (SDF-1a) in the regulation of immunity during health and disease
    • Karin N. The multiple faces of CXCL12 (SDF-1a) in the regulation of immunity during health and disease. J Leukoc Biol 2010; 88(3): 463-73.
    • (2010) J Leukoc Biol , vol.88 , Issue.3 , pp. 463-473
    • Karin, N.1
  • 160
    • 78449300594 scopus 로고    scopus 로고
    • CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression
    • Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metast Rev 2010; 29(4): 709-22.
    • (2010) Cancer Metast Rev , vol.29 , Issue.4 , pp. 709-722
    • Sun, X.1    Cheng, G.2    Hao, M.3    Zheng, J.4    Zhou, X.5    Zhang, J.6
  • 161
    • 77953090345 scopus 로고    scopus 로고
    • CXCL12 (SDF-1)/ CXCR4 pathway in cancer
    • Teicher BA, Fricker SP. CXCL12 (SDF-1)/ CXCR4 pathway in cancer. Clin Cancer Res 2010; 16(11): 2927-31.
    • (2010) Clin Cancer Res , vol.16 , Issue.11 , pp. 2927-2931
    • Teicher, B.A.1    Fricker, S.P.2
  • 162
    • 0035658072 scopus 로고    scopus 로고
    • Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
    • Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7(12): 1339-46.
    • (2001) Nat Med , vol.7 , Issue.12 , pp. 1339-1346
    • Zou, W.1    McHelon, V.2    Coulomb-L'Hermin, A.3    Borvak, J.4    Nome, F.5    Isaeva, T.6
  • 164
    • 19944433608 scopus 로고    scopus 로고
    • Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo
    • Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20(2): 318-29.
    • (2005) J Bone Miner Res , vol.20 , Issue.2 , pp. 318-329
    • Sun, Y.X.1    Schneider, A.2    Jung, Y.3    Wang, J.4    Dai, J.5    Wang, J.6
  • 166
    • 35648945337 scopus 로고    scopus 로고
    • CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature
    • Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA 2007; 104(40): 15735-40.
    • (2007) Proc Natl Acad Sci USA , vol.104 , Issue.40 , pp. 15735-15740
    • Miao, Z.1    Luker, K.E.2    Summers, B.C.3    Berahovich, R.4    Bhojani, M.S.5    Rehemtulla, A.6
  • 168
    • 33750455077 scopus 로고    scopus 로고
    • Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
    • Lee CH, Kakinuma T, Wang J, Zhang H, Palmer DC, Restifo NP, et al. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Mol Cancer Ther 2006; 5(10): 2592-9.
    • (2006) Mol Cancer Ther , vol.5 , Issue.10 , pp. 2592-2599
    • Lee, C.H.1    Kakinuma, T.2    Wang, J.3    Zhang, H.4    Palmer, D.C.5    Restifo, N.P.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.